4//SEC Filing
Galdes Alphonse 4
Accession 0001127602-20-006546
CIK 0000875045other
Filed
Feb 18, 7:00 PM ET
Accepted
Feb 19, 6:13 PM ET
Size
11.7 KB
Accession
0001127602-20-006546
Insider Transaction Report
Form 4
BIOGEN INC.BIIB
Galdes Alphonse
EVP Pharmaceutical Oper & Tech
Transactions
- Exercise/Conversion
Common Stock
2020-02-15+441→ 2,672.264 total - Exercise/Conversion
Restricted Stock Unit
2020-02-15−441→ 333 totalExercise: $0.00Exp: 2020-02-15→ Common Stock (441 underlying) - Tax Payment
Common Stock
2020-02-15$333.00/sh−130$43,290→ 2,542.264 total - Other
Restricted Stock Unit
2020-02-15−333→ 0 totalExercise: $0.00Exp: 2020-02-15→ Common Stock (333 underlying)
Holdings
- 969.366(indirect: By Spouse)
Common Stock
Footnotes (2)
- [F1]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
- [F2]This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Documents
Issuer
BIOGEN INC.
CIK 0000875045
Entity typeother
Related Parties
1- filerCIK 0001789471
Filing Metadata
- Form type
- 4
- Filed
- Feb 18, 7:00 PM ET
- Accepted
- Feb 19, 6:13 PM ET
- Size
- 11.7 KB